This message was sent to ##Email##
Advertisement
|
|
|
|
|
|
Advertisement
|
|
|
SLAS
In a new SLAS Technology original research article available now for free ahead-of-print, researchers in Switzerland describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting. The novelty and importance of this new approach is the combination of the automated musculoskeletal tissue production using 3D bioprinting with a new microwell plate addressing the specific tissue attachment requirements. Thus, this screening platform represents a promising new tool for musculoskeletal drug discovery and development. Image courtesy of Zurich University of Applied Sciences (ZHAW).
READ MORE
Advertisement
SLAS
In a new SLAS Discovery original research article available now for free ahead-of-print, researchers from the Genomics Institute of the Novartis Research Foundation (GNF) highlight a diversity of approaches that their automated high-throughput flow cytometry has enabled for phenotypic drug discovery. Flow cytometry is a very powerful tool that has been used for decades and allows for multiparametric readouts at the single cell level within heterogeneous cell populations. However, in the context of high-throughput screening, flow cytometry is slow, low-throughput, and is not amenable to automation. The GNF group has developed a fully automated screening system that solves this problem.
READ MORE
| |
SPONSORED CONTENT | Advertisement
|
|
Promoted by
|
|
|
|
 |
SLAS
Two recent SLAS Webinars are now available in the SLAS on-demand library. Immerse yourself in either the SLAS2018 follow-up webinar by Sridhar Iyengar, Ph.D., on "Using AI and IoT to Accelerate Research," presented on May 8, or the webinar on "Mitigation and Identification of Aggregation and Nonspecific Reactivity Interference in High-Throughput Screening" by Jayme Dahlin, M.D., Ph.D., presented on June 7. The SLAS on-demand library includes more than 100 presentation recordings and webinars, accessible to SLAS Premier members for free.
READ MORE
| |
PRODUCT SHOWCASE | Advertisement
|
 |
|
Because drug discovery involves scientists from multiple disciplines and often organizations, it is critical to have an efficient mechanism for researchers to collaborate and realize the collective value of their specialized knowledge, assets, and capabilities. This free white paper details the essential keys to effective collaboration.
|
|
SLAS
High-content screening is one of four sessions that support the scientific program of the 2018 SLAS Advanced 3D Human Models and High-Content Analysis Conference, Oct. 17-19, Leiden, Netherlands. Highlighting applications of high-throughput microscopy and multiparametric analysis (otherwise known as high content screening) in both basic and applied research, the session will be led by speakers Beverley Isherwood, Ph.D., of AstraZeneca (UK), and Prisca Liberali, Ph.D., of the Friedrich Miescher Institute for Biomedical Research (FMI, Basel, Switzerland). Come explore the cutting edge of screening with difficult, but physiologically highly relevant cellular systems.
READ MORE
| . |
SPONSORED VIDEO |
Advertisement
|
 |
|
Promoted by
BMG Labtech
Optimizing binding kinetics offers potential clinical benefits. A novel approach determines kinetic parameters such as on- and off-rates by continuous time-resolved FRET reads. This way, the PHERAstar FSX microplate reader simultaneously measures kinetics of hundreds of compounds. Prof. Steven Charlton (Nottingham University) explains how he studies kinetics of ligand-receptor binding.
|
|
SLAS
The Technology Track is one of three informative, innovative tracks at the 2018 SLAS Europe Conference and Exhibition, June 27-29, Brussels, Belgium. Learn more about the track's cutting-edge subject matter that includes: "Organoids and Other Complex Biological Systems in Drug Discovery and Development," "Revolutions in Phenotypic Screening for Modern-Day Drug Discovery" and "Next Generation Analytics."
READ MORE
|
Advertisement
|
|
|
Advertisement
|
|
|
SLAS
Extra! Extra! Read what's new in the latest articles from SLAS Electronic Laboratory Neighborhood (SLAS ELN):
READ MORE
Advertisement
SLAS
Assay Development and Screening, one of 10 educational tracks that form the foundation of the SLAS2019 Scientific Program, reveals recent innovations across the field including the application of new instrumentation, engineered cells and novel assay technologies for compound and genomic screening. The track emphasizes actual recent case studies of development and implementation in screening campaigns with subsequent triage process to confirm and characterize hits. Learn more about planned sessions! Plan to participate: Podium abstracts are due Monday, Aug. 6.
Students: Apply for an SLAS Tony B. Academic Travel Award when you submit your podium or poster abstract. The travel award application and podium abstract deadline is Monday, Aug. 6. The deadline for travel awards for poster abstract submissions is Monday, Sept. 24.
READ MORE
| |
SPONSORED CONTENT | Advertisement
|
|
Promoted by
|
|
|
|
 |
The Scientist
CRISPR doesn't work very well in human cells whose DNA-damage response is working normally. Instead, the genome-editing method selects for cells with a faulty response — one tied to cancer, according to two studies published in Nature Medicine.
"It's something we need to pay attention to, especially as CRISPR expands to more diseases," Sam Kulkarni, the CEO of CRISPR Therapeutics, which was not involved with either study, tells STAT News.
READ MORE
| |
PRODUCT SHOWCASE | Advertisement
|
 |
|
AMRI’s integrated drug discovery centers of excellence combine scientific expertise and leading-edge technology to accelerate innovation. Our complete suite of solutions includes comprehensive discovery biology, synthetic and medicinal chemistry, DMPK and bioanalytical services for successful hit-to-lead-to-candidate selection.
Contact us to put our Discovery expertise to work for you, contact: Customerservice@amriglobal.com.
|
|
Science Daily
An international team of researchers has made CRISPR technology more accessible and standardized by simplifying its complex implementation. The simpler, faster CRISPR, which is presented in the journal Nature Communications, offers a broad platform for off-the shelf genome engineering that may lower the barrier of entry for this powerful technology.
READ MORE
| |
PRODUCT SHOWCASE | Advertisement
|
 |
|
With a straightforward Lab Services Service Contract we increase your instrument’s productivity and extend its life. We guarantee your PlateButler and/or 3rd party devices to be in mint condition. Whether you sign a Full Service Contract or a Preventive Maintenance Contract. Lab Services: a team full of reliable and caring professionals.
We simply accomplish.
|
|
Journal of the American Chemical Society
A high-throughput (HTP) system has been developed to exploit new functional polymers. We synthesized 25 monomers in a mini-HTP manner through the tricomponent Biginelli reaction with high yields. The starting materials were five aldehydes extracted from essential oils. The 25 corresponding polymers were conveniently prepared via mini-HTP radical polymerization initially realizing the benefit of HTP methods to quickly fabricate sample libraries.
READ MORE
|
Advertisement
|
|
|
|
|
Phys.org
Cancer remains one of the major causes of death in Australia and around the world, despite improved treatments and rates of survival.
Traditional chemotherapy treatments have proven to have limitations in how effectively they deliver drugs to the tumour site, causing toxicity to healthy tissues, and failing to prevent the disease from recurring.
READ MORE
Bioscience Technology
Melbourne scientists have discovered how the most important gene in preventing human cancer, p53, is able to stop the development of blood cancers.
The findings revealed that a special group of genes that function within the body’s normal DNA repair process were vital to the effectiveness of p53. This new information could help doctors to better identify patients with an increased risk of developing certain cancers.
READ MORE
Genetic Engineering & Biotechnology News
Gastric bypass surgery is one of the most commonly performed weight-loss procedures in the U.S. and globally. As well as enabling patients to lose significant amounts of weight, the procedure is also better than drug treatment at managing type 2 diabetes, independently of weight loss. However, while the surgery results in multiple benefits to patients, and improved quality of life, relatively few patients will go under the knife.
READ MORE
Chemical & Engineering News
Although many bioanalytical methods study the average behavior of cells across a collection, biologists have started to realize that individual cells often act differently than their neighbors. To learn more about such heterogeneity, researchers need to perform single-cell analyses, but existing methods to do so usually require multiple steps and the addition of fluorescent labels.
READ MORE
Lab Manager
An international team of researchers led by the Max Planck Institute for the Science of Human History has analyzed two 3,800-year-old Y. pestis genomes that suggest a Bronze Age origin for bubonic plague. The strain identified by the researchers was recovered from individuals in a double burial in the Samara region of Russia, who both had the same strain of the bacterium at death.
READ MORE
|
|
Director, Clinical Research – Oncology
Eisai Inc.
US – NJ – Woodcliff Lake
Clinical Geneticist
Mayo Clinic
US – FL – Jacksonville
Program Manager, Clinical Solutions – PAS
Becton Dickinson
US – NJ – Franklin Lakes
Search Jobs at SLAS Career Connections
| | THANK YOU 2018 SLAS CORPORATE MEMBERS |
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
Optimized for drug screening and new indication research
